| [ Summary ] |
The incidence of proteinuria seen in glomerulonephritis and nephrotic syndrome patients induces abnormal balances in the coagulation and fibrinolytic systems. In particular, coagulation factors produced from increased liver activity as well as lowered molecular fibrinolytic factors leads to a decrease in nephrotic syndrome. This leads to a state of hyper-coagulability. Additionally, a complex disease condition comprised of disorders in platelets and the endothelia, intravascular dehydration, tissue edema and hyperlipidemia elevates the incidence of thrombosis. Thus, anticoagulant and antiplatelet therapy is necessary for treatment of glomerulonephritis and nephrotic syndrome, in order to prevent thrombosis. Combined anticoagulant and antiplatelet therapy alone has the ability to provide anti-proteinuric effects for treatment of glomerulonephritis and nephrotic syndrome. |